PL8331 / Palatin Technologies - LARVOL DELTA

Stimulating the Melanocortin System in Uveitis and Diabetes Preserves the Structure and Anti-Inflammatory Activity of the Retina. (PubMed, Int J Mol Sci) - "In addition, retinal pigment epithelial cells (RPE) from PL-8331-treated diabetic mice retained normal anti-inflammatory activity. The results demonstrated that the pan-melanocortin receptor agonist PL-8331 is a potent therapeutic drug to suppress inflammation, prevent retinal degeneration, and preserve the normal anti-inflammatory activity of RPE."

Journal • CNS Disorders • Diabetes • Diabetic Retinopathy • Genetic Disorders • Immunology • Inflammation • Metabolic Disorders • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis

The Effects Of Melanocortin Receptor Agonists On Experimental Autoimmune Uveitis (ARVO 2022) - "When the mice reached the chronic stage of EAU, they were injected twice one-day apart with 50 µg of α-MSH (pan-agonist), PL8331 (pan-agonist), PL8177 (potent MC1r-only agonist), PL5000 (same as α-MSH but no MC5r functional activity), MT-II (same as PL5000) or PG901 (MC5r agonist, but an antagonist to MC3r, and MC4r). In this study, we investigated the effects of α-MSH-analogs in suppressing EAU. Our previous studies showed the importance of the melanocortins in the maintenance of ocular immune privilege and that α-MSH-treatment accelerated recovery and induced retinal-antigen-specific regulatory immunity. Our current results demonstrated that α-MSH-analogs targeting MC1r and MC5r together have a therapeutic potential to suppress uveitis and induce regulatory immunity."

Ocular Inflammation • Ophthalmology • Uveitis • IL10 • IL17A

Melanocortin receptor agonists suppress experimental autoimmune uveitis. (PubMed, Exp Eye Res) - "The α-MSH-analogs were a pan-agonist PL8331, PL8177 (potent MC1r-only agonist), PL5000 (a pan-agonist with no MC5r functional activity), MT-II (same as PL5000) and PG901 (MC5r agonist, but also an antagonist to MC3r, and MC4r). Our current results show that this activity is centered around MC1r and MC5r. In addition, the results suggest that a therapeutic potential to target MC1r and MC5r together to suppress uveitis induces regulatory immunity with potentially maintaining a normal retinal structure."

Journal • Immune Modulation • Immunology • Inflammation • Ocular Inflammation • Ophthalmology • Uveitis • IL10 • IL17A